Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Pulse Biosciences, Inc.

pulsebiosciences.com
Filed: Apr 8, 2026CIK: 0001625101Biotechnology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Pulse Biosciences appointed Liane R. Teplitsky as Chief Operating Officer effective April 8, 2026. This strategic hire brings extensive medical device and commercialization experience from Abbott Laboratories, St. Jude Medical, and Artedrone, positioning the company to strengthen operational capabilities and advance its medical technology initiatives.

Key Takeaways

Liane R. Teplitsky appointed as new Chief Operating Officer with proven track record as CEO of Artedrone and senior roles at major medical device companies

Appointment expected to enhance operational management and strategic focus on autonomous robotic technology for stroke treatment

1 more takeaway

Related Filings (9)

9 more filings from Pulse Biosciences, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateApr 8, 2026
Item5.02
CategoryExecutive Change
CIK0001625101
Accession #plse20260316_8k.htm
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
executive hireleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings